Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance
SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternativ
Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Financial HighlightsFourth Quarter Ended December 31, 2023 Net revenue from continuing operations was $3.3 million, compared to $2.6 million in the fourth quarter of 2022, up 27%Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2022Adjusted EBITDA from co
B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50
Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance
SOUTH ORANGE, NJ, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its second-quarter financial results on Thursday, August 8, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows: Domestic access: 1 (844) 808-7106 International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternativ
Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023. Financial HighlightsFourth Quarter Ended December 31, 2023 Net revenue from continuing operations was $3.3 million, compared to $2.6 million in the fourth quarter of 2022, up 27%Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2022Adjusted EBITDA from co
SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv
SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment
- Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
4 - NEPHROS INC (0001196298) (Issuer)
The Dow Jones index closed lower by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Nephros The Trade: Nephros, Inc. (NASDAQ:NEPH) Director Arthur H Amron bought a total of 5,000 shares at an average price of $2.24. To acquire these shares, it cost around $11,176. What's Happening: On May 9, Nephros posted a narrower-than-expe
Benchmark analyst Robert Wasserman reiterates Nephros (NASDAQ:NEPH) with a Speculative Buy and maintains $5 price target.
-SEC Filing
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
SC 13G - NEPHROS INC (0001196298) (Subject)
8-K - NEPHROS INC (0001196298) (Filer)
10-Q - NEPHROS INC (0001196298) (Filer)
S-8 - NEPHROS INC (0001196298) (Filer)